论文部分内容阅读
目的:探讨血清谷氨酸脱羧酶抗体(glutamic acid decarboxylase antibody,GADA)在慢性肝病中的临床意义。方法:采用ELISA法检测242例慢性肝病患者及30例同期健康体检者(对照组)血清GADA,分析血清GADA阳性率与丙型肝炎病毒、乙型肝炎病毒、肝病严重程度、血糖及血清抗核抗体等自身抗体阳性的关系。结果:慢性肝病患者血清GADA阳性率高于对照组(P<0.05);丙型肝炎病毒相关肝病组高于乙型肝炎病毒相关肝病组(P<0.05),肝源性糖尿病组高于肝病血糖正常组,肝硬化组高于肝炎组(P<0.05),自身抗体阳性组高于自身抗体阴性组(P<0.05)。结论:慢性肝病合并自身抗体阳性者血清GADA阳性率更高,可能预示着更高的肝源性糖尿病发生率。
Objective: To investigate the clinical significance of serum glutamic acid decarboxylase antibody (GADA) in chronic liver disease. Methods: Serum GADA was detected by ELISA in 242 patients with chronic liver disease and 30 healthy people at the same period (control group). The positive rates of serum GADA and hepatitis C virus, hepatitis B virus, severity of liver disease, blood glucose and serum anti-nuclear Antibodies and other autoantibodies positive relationship. Results: The positive rate of serum GADA in patients with chronic liver disease was higher than that of the control group (P <0.05), higher in hepatitis C virus-related liver disease group than in hepatitis B virus-related liver disease group (P <0.05), higher in liver-derived diabetes group than in liver disease The normal group and the cirrhosis group were higher than those in the hepatitis group (P <0.05), and the autoantibody positive group was higher than the autoantibody negative group (P <0.05). Conclusion: The positive rate of serum GADA in patients with chronic liver disease complicated with autoantibodies is higher, which may indicate the higher incidence of liver-derived diabetes.